ForU Holdings, Inc.

ForU Holdings, Inc., a wellness solutions company, through its subsidiaries, provides nutritional products and healthcare services. The company engages in researching and developing branded consumer products in the health and wellness space, including functional food and beverages; providing a suite of in-home non-medical and medical staffing and services, including light housekeeping and transportation, nurse and doctor visits, occupational and physical therapy, and other clinical services; and operating Wish Upon A Hero (WUAH), an online community that connects people in need with people who can help. It is also involved in the development of an orally administered product for the treatment of pediatric diarrhea in India; and provision of DNA customized nutritional supplements, skin care, and gene modulating weight management products through self-directed businesses. The company was formerly known as Capsalus Corp. and changed its name to ForU Holdings, Inc. in July 2014. ForU Holdings, Inc. is headquartered in Barrington, Illinois.

ForU Holdings, Inc. trades as FORU on OTC. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$16.03M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

ForU Holdings, Inc. can be compared against peers such as Anthera Pharmaceuticals, Inc., Cotinga Pharmaceuticals Inc., Wayland Group Corp., Greenwind Holdings Inc., Neurobiological Technologies, Inc., ONE Bio Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2,171, beta of 0.00, and return on equity of +605.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FORU currently shows total debt of $3.18M and beta of 0.00. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.capsalus.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.